Taipei Exchange - Delayed Quote TWD

Alar Pharmaceuticals Inc. (6785.TWO)

141.00
-1.00
(-0.70%)
At close: June 13 at 1:30:07 PM GMT+8

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in TWD.
NameTitlePayExercisedYear Born
Dr. Yung-Shun Wen Ph.D. CEO & Director -- -- --
Ms. Vivian Kang Accounting Supervisor & Director of Finance -- -- --

Alar Pharmaceuticals Inc.

No. 32, Keya Road
5th Floor Daya District
Taichung
Taiwan
886 4 2463 7115 https://www.alarpharm.com
Sector: 
Healthcare
Full Time Employees: 
27

Description

Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. The company develops ALA-1000 for the treatment of opioid use disorder. Its pre-clinical stage product includes ALA-1300 and ALA-2000 for the treatment of opioid use disorder; ALA-4000 to treat Parkinson's disease; ALA-3000 for treating treatment-resistant depression; and ALA-5000 to treat schizophrenia. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.

Corporate Governance

Alar Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

June 10, 2025 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers